All News

Use of menopausal hormone therapy decreased from nearly 27% to 5% among postmenopausal women between 1999 and 2020, according to new research.

Are your patients asking about Ozempic and other GLP-1RAs? Are you prescribing it? Take our quick survey.

Surya Bhatt, MD, MSPH, is coprincipal investigator for the 2 pivotal phase 3 clinical trials that supported today's landmark FDA approval of dupilumab for COPD.

Dupilumab represents the first new treatment approach for uncontrolled COPD in more than a decade and reduced disease exacerbations by 34% in clinical trials.

Cobenfy, previously KarXT, is the first new agent with a novel mechanism of action for schizophrenia in more than 50 years, according to BMS.

Your daily dose of the clinical news you may have missed.

A 2-year-old child has had a low-grade fever for 4 days and a swelling has developed behind the left ear. She just recovered from a URI. What's your diagnosis?

Updated mRNA COVID-19 vaccines, the first orally disintegrating tablet approved for pregnancy prevention, and 5 more.

Your daily dose of the clinical news you may have missed.

Among adolescents and adults with moderate-to-severe AD, more than 80% achieved sustained disease control, the majority not requiring topical or systemic rescue medication.

Roflumilast cream 0.15% was associated with consistent and meaningful improvements in AD clearance and itch reduction, according to new data.

The risk of gestational diabetes was 2-fold greater among young women with prediabetes before conceiving compared with those who had normoglycemia.

A continuous increase in ASCVD risk was seen with higher levels of lipoprotein(a) in the largest study to date of the relationship.

Your daily dose of the clinical news you may have missed.

How are you managing your patients with resistant or refractory hypertension? How do your strategies align with current guidelines? Try these 9 questions and find out.

JoAnn Pinkerton, MD, details the positive findings from the OASIS 1, 2, and 3 studies of elinzanetant and highlights next steps in research.

Delgocitinib specifically inhibits activation of JAK-STAT signaling in chronic hand eczema and would be an option for people unable to use topical corticosteroids.

Your daily dose of the clinical news you may have missed.